Skip to content

Liquid biopsy for early detection of cancer

Realtime Enrichment Screen for Outright detection of Latent Undiagnosed malignant Tumors in asymptomatic individuals Efficiently - RESOLUTE

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/01/017219
Enrollment
61200
Registered
2019-01-23
Start date
Unknown
Completion date
Unknown
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

None listed

Sponsors

Datar Cancer Genetics Limited
Lead Sponsor
Canconnect Foundation
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Non-cancer arm- For Inclusion, an individual must meet all of the following criteria: 1.Age â?? 49 to 75 years for males and 40 to 75 years for females 2.Participants with no known diagnosis or past history of cancer 3.Willingness to provide blood sample as per study protocol 4.Patient should be willing for screening investigations proposed in study protocol. 5.Female patient is not pregnant / lactating (self-report) 6.Provision of signed informed consent form and expresses understanding of the protocol and its requirements, risks, and discomforts. 7.Stated willingness to comply with all study procedures Cancer arm- For Inclusion, an individual must meet all of the following criteria: 1.Age â?? 49 to 75 years for males and 40 to 75 years for females 2.Able to provide a written informed consent 3.Have either of the following: a.Confirmed cancer diagnosis (any stage I-IV) within 90 days prior to study blood draw, based upon assessment of a pathological specimen and are therapy naïve at the time of blood collection OR b.A high suspicion for a cancer diagnosis by clinical and/or radiological assessment, with planned biopsy or surgical resection to establish a definitive diagnosis within 6 weeks (42 days) after study blood draw and are therapy naïve at the time of blood collection 4.Willingness to provide blood sample as per study protocol 5.Female patient is not pregnant / lactating (self-report) 6.Provision of signed informed consent form and expresses understanding of the protocol and its requirements, risks, and discomforts. 7.Stated willingness to comply with all study procedures Benign lesions arm- For Inclusion, an individual must meet all of the following criteria: 1.Age â?? 49 to 75 years for males and 40 to 75 years for females 2.Able to provide a written informed consent 3.Have either of the following: a.Confirmed diagnosis of a benign lump within 90 days prior to study blood draw, based upon assessment of a pathological specimen and are therapy naïve at the time of blood collection OR b.A high suspicion for a benign lump by clinical and/or radiological assessment, with planned biopsy or surgical resection to establish a definitive diagnosis within 6 weeks (42 days) after study blood draw and are therapy naïve at the time of blood collection 4.Willingness to provide blood sample as per study protocol 5.Female patient is not pregnant / lactating (self-report) 6.Provision of signed informed consent form and expresses understanding of the protocol and its requirements, risks, and discomforts. 7.Stated willingness to comply with all study procedures

Exclusion criteria

Exclusion criteria: Non-cancer arm- For Exclusion, an individual may meet any of the following criteria: 1.Known current or prior diagnosis of cancer 2.Unable to provide informed consent 3.Unable to comply with all project screening procedures 4.Current treatment with any investigational drug or intervention 5.Pregnant or lactating women (by self-report) 6.Age less than 49 or more than 75 years for males and less than 40 or more than 75 years for females 7.Unable/unwilling to provide blood sample as per study requirement. 8.Oral or IV corticosteroid use in past 14 days prior to blood draw 9.Current febrile illness 10.Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw. 11.History of blood transfusion/ PET-CT scan/CT-scan in last 30 days Cancer arm- For Exclusion, an individual may meet any of the following criteria: 1.Known prior history of cancer or history of prior or current cancer treatment 2.Unable to provide informed consent 3.Unable to comply with all project screening procedures 4.Current treatment with any investigational drug or intervention 5.Pregnant or lactating women (by self-report) 6.Age less than 49 or more than 75 years for males and less than 40 or more than 75 years for females 7.Unable/unwilling to provide blood sample as per study requirement. 8.Oral or IV corticosteroid use in past 14 days prior to blood draw 9.Current febrile illness 10.Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw. 11.History of blood transfusion/ PET-CT scan/CT-scan in last 30 days Benign lesions arm- For Exclusion, an individual may meet any of the following criteria: 1.Known prior history of cancer or history of prior or current cancer treatment or a high suspicion for a cancer diagnosis 2.Unable to provide informed consent 3.Unable to comply with all project screening procedures 4.Current treatment with any investigational drug or intervention 5.Pregnant or lactating women (by self-report) 6.Age less than 49 or more than 75 years for males and less than 40 or more than 75 years for females 7.Unable/unwilling to provide blood sample as per study requirement. 8.Oral or IV corticosteroid use in past 14 days prior to blood draw 9.Current febrile illness 10.Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw. 11.History of blood transfusion/ PET-CT scan/CT-scan in last 30 days

Design outcomes

Primary

MeasureTime frame
SpecificityTimepoint: 12 months

Secondary

MeasureTime frame
SensitivityTimepoint: 12 months

Countries

India

Contacts

Public ContactDr Darshana Patil

Datar Cancer Genetics Limited

dadasaheb.akolkar@datarpgx.com7387705888

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026